keyword
MENU ▼
Read by QxMD icon Read
search

Aflibercept

keyword
https://www.readbyqxmd.com/read/28816730/intravitreal-injection-of-aflibercept-in-patients-with-polypoidal-choroidal-vasculopathy-a-3-year-follow-up
#1
Maiko Maruyama-Inoue, Shimpei Sato, Shin Yamane, Kazuaki Kadonosono
PURPOSE: To compare the 3-year follow-up results of intravitreal injections of aflibercept between fixed dosing (FD) regimen and a pro re nata (PRN) regimen after three initial monthly doses for the treatment of polypoidal choroidal vasculopathy and to analyze factors influencing improvement in visual acuity. METHODS: We retrospectively studied all treatment-naive patients with polypoidal choroidal vasculopathy who were scheduled to receive intravitreal aflibercept injections FD or PRN after induction treatment between March 2013 and May 2014...
August 14, 2017: Retina
https://www.readbyqxmd.com/read/28814412/long-term-outcomes-with-as-needed-aflibercept-in-diabetic-macular-oedema-2-year-outcomes-of-the-endurance-extension-study
#2
Charles C Wykoff, William C Ou, Rahul N Khurana, David M Brown, W Lloyd Clark, David S Boyer
BACKGROUND/AIMS: To evaluate the efficacy and safety of individualised 2.0 mg intravitreal aflibercept retreatment for diabetic macular oedema (DME) through the fifth year of management. METHODS: This is a phase IV, 2-year, open-label extension study. Sixty patients completing the 3-year VISTA DME (Study of Intravitreal Aflibercept Injection in Patients With Diabetic Macular Edema) phase III trial enrolled in the ENDURANCE (Long-Term Efficacy and Safety of Intravitreal Aflibercept for the Treatment of DME in Subjects Who Completed the VISTA DME Trial) extension study...
August 16, 2017: British Journal of Ophthalmology
https://www.readbyqxmd.com/read/28810842/erratum-to-short-term-efficacy-of-intravitreal-aflibercept-injections-for-retinal-angiomatous-proliferation
#3
Hung-Da Chou, Wei-Chi Wu, Nan-Kai Wang, Lan-Hsin Chuang, Kuan-Jen Chen, Chi-Chun Lai
No abstract text is available yet for this article.
August 15, 2017: BMC Ophthalmology
https://www.readbyqxmd.com/read/28807738/observed-benefit-and-safety-of-aflibercept-in-elderly-patients-with-metastatic-colorectal-cancer-an-age-based-analysis-from-the-randomized-placebo-controlled-phase-iii-velour-trial
#4
Paul Ruff, Eric Van Cutsem, Radek Lakomy, Jana Prausova, Guy A van Hazel, Vladimir M Moiseyenko, Karen Soussan-Lazard, Emmanuelle Dochy, Emmanuelle Magherini, Teresa Macarulla, Demetris Papamichael
OBJECTIVES: Aflibercept (ziv-aflibercept) significantly improves progression-free (PFS) and overall survival (OS) when added to 5-fluorouracil, leucovorin and irinotecan (FOLFIRI), compared with FOLFIRI alone, in patients with metastatic colorectal cancer previously treated with oxaliplatin-based therapy. This subset analysis of the VELOUR study investigates aflibercept plus FOLFIRI versus placebo plus FOLFIRI according to age. METHODS: Efficacy and safety were analyzed by treatment arm and age (≥ or <65years)...
August 12, 2017: Journal of Geriatric Oncology
https://www.readbyqxmd.com/read/28803666/-inefficacy-of-aflibercept-in-the-treatment-of-idiopathic-macular-telangiectasia-type-2%C3%A2-without-neovascularization
#5
J Bénichou, V Soler, D Denis, F Matonti
Idiopathic macular telangectasia type 2 is a rare disease consisting primarily of bilateral macular capillary telangiectasia, alterations of the ellipsoid zone and intraretinal cysts that may appear as cystoid macular edema in the absence of neovascularization. Our goal was to study the efficacy of aflibercept in the treatment of these cysts. Thus, we performed a series of three intravitreal injections of aflibercept in the right eye of a woman with a typical presentation of macular telangectasia type 2 complicated by cystoid macular edema without neovascularization...
August 10, 2017: Journal Français D'ophtalmologie
https://www.readbyqxmd.com/read/28801117/incidence-and-outcomes-of-infectious-and-noninfectious-endophthalmitis-after-intravitreal-injections-for-age-related-macular-degeneration
#6
Vincent Daien, Vuong Nguyen, Rohan W Essex, Nigel Morlet, Daniel Barthelmes, Mark C Gillies
PURPOSE: To assess the incidence, cumulative rate, and long-term outcomes of infectious and noninfectious endophthalmitis after intravitreal injections (IVTs) of anti-vascular endothelial growth factor (VEGF) agents. DESIGN: Database study, prospectively designed. PARTICIPANTS: Treatment-naïve eyes with neovascular age-related macular degeneration (nAMD) tracked by the Fight Retinal Blindness! (FRB!) registry that commenced anti-VEGF therapy between January 1, 2006, and November 30, 2016...
August 8, 2017: Ophthalmology
https://www.readbyqxmd.com/read/28798980/two-year-outcome-of-an-observe-and-plan-regimen-for-neovascular-age-related-macular-degeneration-treated-with-aflibercept
#7
Parmis Parvin, Marta Zola, Ali Dirani, Aude Ambresin, Irmela Mantel
PURPOSE: The purpose of our study was to investigate the two-year outcome of Aflibercept treatment for neovascular age-related macular degeneration (nAMD), using the Observe-and-Plan regimen, an individually planned treatment regimen, based on the predictability of an individual's need for retreatment, aiming to reduce the clinical burden. METHODS: Our prospective study used the Observe-and-Plan regimen with Aflibercept to treat nAMD: Three loading doses, followed by monthly observation visits until the disease-recurrence interval was determined, which then was shortened by 2 weeks in a treatment plan for the next three injections without intermediate monitoring visits...
August 10, 2017: Graefe's Archive for Clinical and Experimental Ophthalmology
https://www.readbyqxmd.com/read/28796997/dynamics-of-inflammatory-factors-in-aqueous-humor-during-ranibizumab-or-aflibercept-treatment-for-age-related-macular-degeneration
#8
Ryosuke Motohashi, Hidetaka Noma, Kanako Yasuda, Osamu Kotake, Hiroshi Goto, Masahiko Shimura
PURPOSE: To evaluate the dynamic changes of the aqueous humor levels of inflammatory factors between patients receiving intravitreal ranibizumab injection (IRI) and aflibercept injection (IAI) in patients with exudative age-related macular degeneration (AMD). METHODS: The study was performed on 30 eyes with AMD that were scheduled to receive 3 doses of IRI (15 eyes) or IAI (15 eyes) at monthly intervals. Aqueous humor samples were collected when injection was done...
August 11, 2017: Ophthalmic Research
https://www.readbyqxmd.com/read/28792245/a-phase-2-study-of-5-fluorouracil-5-fu-ziv-aflibercept-and-radiation-for-the-preoperative-and-adjuvant-treatment-of-patients-with-stage-ii-iii-rectal-cancer
#9
Johanna C Bendell, Dana Thompson, Brian M Hemphill, David Wenk, Chris Earwood, Cassie M Lane, Andrew Kennedy
BACKGROUND: This phase II study combined aflibercept with preoperative chemoradiation for patients with stage II/III rectal cancer, followed by mFOLFOX6/aflibercept. METHODS: Patients received preoperative 5-FU (days 1-43), radiation (weeks 1-6), and aflibercept (days 1-15) each 28 day cycle for 6 weeks. Six weeks following the last aflibercept dose, patients underwent surgical resection. Four cycles of mFOLFOX6 plus aflibercept began 8 weeks after surgery. RESULTS: Common treatment-related toxicities included diarrhea, fatigue, and mucositis...
August 9, 2017: Cancer Investigation
https://www.readbyqxmd.com/read/28772268/baseline-optical-coherence-tomography-findings-as-outcome-predictors-after-switching-from-ranibizumab-to-aflibercept-in-neovascular-age-related-macular-degeneration-following-a-treat-and-extend-regimen
#10
Cengiz Türksever, Christian Prünte, Katja Hatz
PURPOSE: To evaluate outcome predictors of aflibercept in neovascular age-related macular degeneration pretreated with ranibizumab based on a treat-and-extend regimen (TER). METHODS: We performed a retrospective evaluation of 18-month follow-up of 45 consecutive patients with limited response to ranibizumab. RESULTS: At month 18, mean central retinal thickness and intraretinal fluid (IRF) height were significantly reduced. The recurrence-free treatment interval (RFTI) increased from 7...
August 4, 2017: Ophthalmologica. Journal International D'ophtalmologie
https://www.readbyqxmd.com/read/28769551/intravitreal-aflibercept-for-choroidal-neovascularization-associated-with-chorioretinitis-a-pilot-study
#11
Andrii R Korol, Oleksandra Zborovska, Taras Kustryn, Oleksandra Dorokhova, Nataliya Pasyechnikova
PURPOSE: The purpose of this study was to evaluate the potential benefits of intravitreal aflibercept injections for the treatment of choroidal neovascularization (CNV) secondary to chorioretinitis. METHODS: In this uncontrolled, prospective cohort study, 15 eyes of 14 consecutive patients affected by CNV associated with ocular toxoplasmosis were treated with intravitreal aflibercept (2 mg) pro re nata and observed over a 12-month follow-up period. The primary outcome was the change in best-corrected visual acuity (BCVA) from baseline to month 12...
2017: Clinical Ophthalmology
https://www.readbyqxmd.com/read/28768426/necrotising-fasciitis-in-a-patient-treated-with-folfiri-aflibercept-for-colorectal-cancer-a-case-report
#12
A Gonzaga-López, J Muñoz-Rodriguez, A Ruiz-Casado
Anti-angiogenics have become an important part of the treatment of several types of tumours such as ovarian, breast, lung and colorectal cancer. Necrotising fasciitis has been reported with bevacizumab but no cases have been reported with aflibercept, ramucirumab or regorafenib in patients with colorectal cancer. Necrotising fasciitis is a rare complication affecting one in 5000 bevacizumab users. We report the case of a 64-year-old man with stage IV rectosigmoid cancer under treatment with folinic acid, fluorouracil and irinotecan (FOLFIRI) and aflibercept, who developed a Fournier's gangrene...
August 3, 2017: Annals of the Royal College of Surgeons of England
https://www.readbyqxmd.com/read/28767552/efficacy-and-frequency-of-intravitreal-aflibercept-versus-bevacizumab-for-macular-edema-secondary-to-central-retinal-vein-occlusion
#13
Ayman Lotfy, Kamal A M Solaiman, Ayman Abdelrahman, Ahmed Samir
PURPOSE: To compare the safety, efficacy, and frequency of intravitreal injection of aflibercept and bevacizumab for treatment of macular edema secondary to central retinal vein occlusion. DESIGN: Prospective, comparative, randomized, interventional study. PATIENTS AND METHODS: Eyes with macular edema secondary to central retinal vein occlusion were randomized between two groups according to the intravitreal injection used. Group A included eyes treated with intravitreal aflibercept, and Group B included eyes treated with intravitreal bevacizumab injections...
August 1, 2017: Retina
https://www.readbyqxmd.com/read/28767550/impact-of-long-term-intravitreal-anti-vascular-endothelial-growth-factor-on-preexisting-microstructural-alterations-in-diabetic-macular-edema
#14
Magdalena A Wirth, Juliana Wons, Florentina J Freiberg, Matthias D Becker, Stephan Michels
PURPOSE: Evaluation of the influence of long-term intravitreal anti-vascular endothelial growth factor treatment on preexisting retinal microstructural alterations in patients with diabetic macular edema. METHODS: Eyes with diabetic macular edema and a history of ≥ 20 intravitreal anti-vascular endothelial growth factor (aflibercept and/or ranibizumab) injections were included in this retrospective study. Primary outcome was the extent of disorganization of retinal inner layers, alterations at the outer plexiform layer/Henle fiber layer junction, disruption of external limiting membrane/ellipsoid zone, disruption of retinal pigment epithelium/Bruch complex, and retinal atrophy at baseline versus after ≥ 20 intravitreal injections as visualized by spectral-domain optical coherence tomography images...
August 1, 2017: Retina
https://www.readbyqxmd.com/read/28764888/baseline-factors-affecting-changes-in-diabetic-retinopathy-severity-scale-score-after-intravitreal-aflibercept-or-laser-for-diabetic-macular-edema-post-hoc-analyses-from-vista-and-vivid
#15
Dilsher S Dhoot, Keith Baker, Namrata Saroj, Robert Vitti, Alyson J Berliner, Carola Metzig, Desmond Thompson, Rishi P Singh
PURPOSE: To evaluate whether select baseline systemic and ocular factors influence ≥2-step improvement in the Diabetic Retinopathy Severity Scale (DRSS) score at week 100 in VISTA and VIVID. DESIGN: Post hoc analysis of 2 similarly designed phase 3 trials, VISTA and VIVID. PARTICIPANTS: Total of 456 patients with center-involved diabetic macular edema (DME). METHODS: VISTA and VIVID randomized 872 DME patients to receive intravitreal aflibercept injection (IAI) 2 mg every 4 weeks (2q4), IAI 2 mg every 8 weeks after 5 monthly doses (2q8), or macular laser photocoagulation...
July 29, 2017: Ophthalmology
https://www.readbyqxmd.com/read/28761750/european-medicines-agency-approval-summary-zaltrap-for-the-treatment-of-patients-with-oxaliplatin-resistant-metastatic-colorectal-cancer
#16
REVIEW
Stefan Cristian Stanel, Jan Sjöberg, Tomas Salmonson, Paolo Foggi, Mariapaola Caleno, Daniela Melchiorri, Iordanis Gravanis, Kyriaki Tzogani, Francesco Pignatti
On 1 February 2013, a marketing authorisation valid throughout the European Union was issued for aflibercept (Zaltrap) in combination with irinotecan/5-fluorouracil/folinic acid chemotherapy for the treatment of adults with metastatic colorectal cancer resistant to or progressive after an oxaliplatin-containing regimen. Aflibercept is a recombinant fusion protein which blocks the activation of vascular endothelial growth factor (VEGF) receptors and the proliferation of endothelial cells, acting as a soluble decoy receptor that binds to VEGF-A with higher affinity than its native receptors, as well as placental growth factor and VEGF-B...
2017: ESMO Open
https://www.readbyqxmd.com/read/28758110/comparisons-of-efficacy-of-intravitreal-aflibercept-and-ranibizumab-in-eyes-with-diabetic-macular-edema
#17
Norihiro Shimizu, Toshiyuki Oshitari, Tomoaki Tatsumi, Yoko Takatsuna, Miyuki Arai, Eiju Sato, Takayuki Baba, Shuichi Yamamoto
We compared the efficacy of intravitreal aflibercept (IVA) to intravitreal ranibizumab (IVR) injections in eyes with diabetic macular edema (DME). The medical records of 49 eyes of 36 patients who were diagnosed with DME and had received IVR and 46 eyes of 40 patients who had received IVA treatment were reviewed. The central macular thickness (CMT) and best-corrected visual acuity (BCVA) were measured at the baseline and at 1, 3, and 6 months after the IVR or IVA. The mean number of injections of IVR was 2...
2017: BioMed Research International
https://www.readbyqxmd.com/read/28743128/anti-vascular-endothelial-growth-factors-protect-retinal-pigment-epithelium-cells-against-oxidation-by-modulating-nitric-oxide-release-and-autophagy
#18
Stefano De Cillà, Serena Farruggio, Stela Vujosevic, Giulia Raina, Davide Filippini, Valentina Gatti, Nausicaa Clemente, David Mary, Diego Vezzola, Giamberto Casini, Luca Rossetti, Elena Grossini
BACKGROUND/AIMS: the anti-vascular endothelial growth factors (VEGF), Aflibercept and Ranibizumab, are used for the treatment of macular degeneration. Here we examined the involvement of nitric oxide (NO), mitochondria function and of apoptosis/autophagy in their antioxidant effects in human retinal pigment epithelium cells (RPE). METHODS: RPE were exposed to Ranibizumab/Aflibercept in the absence or presence of NO synthase (NOS) inhibitor and of autophagy activator/blocker, rapamicyn/3-methyladenine...
July 25, 2017: Cellular Physiology and Biochemistry
https://www.readbyqxmd.com/read/28736761/phase-ii-study-of-dovitinib-in-patients-progressing-on-anti-vascular-endothelial-growth-factor-therapy
#19
Thomas J Semrad, Edward J Kim, Michael S Tanaka, Jacob Sands, Chris Roberts, Rebekah A Burich, Yu Li, David R Gandara, Primo Lara, Philip C Mack
BACKGROUND: Prior work identified the fibroblast growth factor (FGF) pathway as a mediator of resistance to anti-vascular endothelial growth factor (VEGF) therapy. We tested dovitinib, an inhibitor of both FGF and VEGF receptors, in patients progressing on anti-VEGF treatment. METHODS: Patients with measurable advanced colorectal or non-small cell lung cancer with progression despite anti-VEGF treatment within 56 days, good performance status and adequate organ function were eligible...
2017: Cancer Treat Res Commun
https://www.readbyqxmd.com/read/28736636/biological-agents-in-gastrointestinal-cancers-adverse-effects-and-their-management
#20
REVIEW
Nivedita Arora, Arjun Gupta, Preet Paul Singh
Biological therapy comprises agents that by virtue of their unique mechanisms of action, are able to specifically incite a response against or target malignant cells. They differ from conventional chemotherapy with regard to mechanisms of action, indications and side effect profile. Biologic agents have revolutionized therapy for a number of malignancies. In the setting of gastrointestinal (GI) malignancies, agents targeting vascular endothelial growth factor (VEGF), human epidermal growth factor receptor 2 (Her2/Neu) and epidermal growth factor receptor (EGFR) have proven to be invaluable additions to chemotherapy...
June 2017: Journal of Gastrointestinal Oncology
keyword
keyword
1772
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"